Founder Lodge | Atalanta Therapeutics raises $75,000,000 at Series …

Jan 29, 2025 · Atalanta Therapeutics raises $75,000,000 at Series B on 2025-01-29 in Biotechnology Research, industry founded/co-founded by Alicia Secor

CouponFollow Extension

$75000000
OFF

Founder Lodge | Atalanta Therapeutics Raises $75,000,000 At Series …

3 weeks from now

Jan 29, 2025 · Atalanta Therapeutics raises $75,000,000 at Series B on 2025-01-29 in Biotechnology Research, industry founded/co-founded by Alicia Secor

founderlodge.com

$97
OFF

Atalanta Gets $97 Million Series B To Target Neurological

3 weeks from now

Jan 28, 2025 · Atalanta Therapeutics, a Boston-based biotechnology company focused on neurological diseases, announced Monday the completion of a $97 million series B financing …

biospace.com

$110
OFF

Atalanta Therapeutics Funded $110M For ... - Angel Investors

3 weeks from now

Jan 11, 2021 · Atalanta founded to address the significant constraint for today’s RNAi therapeutics: the struggle of achieving distribution, ultimately the brain and spinal cord. …

funded.com

$11000000
OFF

Founder Lodge | Doron Therapeutics Raises $11,000,000 At Series A …

3 weeks from now

Nov 27, 2024 · Doron Therapeutics raises $11,000,000 at Series A on 2024-11-27 in Biotechnology Research, industry founded/co-founded by Alessandra Pavesio ... Atalanta …

founderlodge.com

$300000000
OFF

Founder Lodge | Kardigan Raises $300,000,000 At Series A On 2025 …

3 weeks from now

Jan 14, 2025 · Kardigan raises $300,000,000 at Series A on 2025-01-14 in Biotechnology Research, industry founded/co-founded by Tassos Gianakakos

founderlodge.com

$65000000
OFF

Founder Lodge | ONL Therapeutics Raises $65,000,000 At Series D …

3 weeks from now

Sep 17, 2024 · ONL Therapeutics raises $65,000,000 at Series D on 2024-09-17 in Biotechnology Research, industry founded/co-founded by David Esposito

founderlodge.com

FAQs about Founder Lodge | Atalanta Therapeutics raises $75,000,000 at Series … Coupon?

Who is Atalanta Therapeutics?

About Atalanta Therapeutics Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing its proprietary RNA interference platform. ...

Does Atalanta therapeutics have a series a financing?

BOSTON, Mass. – Jan. 11, 2021 – Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases, launched today with a Series A financing exclusively by F-Prime Capital. Additionally, Atalanta announced strategic collaborations with Biogen (Nasdaq: BIIB) and Genentech, a member of the Roche Group. ...

How much money has Atalanta Therapeutics raised?

The current revenue for Atalanta Therapeutics is . How much funding has Atalanta Therapeutics raised over time? Atalanta Therapeutics has raised $300M. Who are Atalanta Therapeutics’s investors? Abrdn, EQT Life Sciences, GHR Foundation, Mirae Asset Capital, and Novartis are 5 of 11 investors who have invested in Atalanta Therapeutics. ...

What's going on with Atalanta Therapeutics?

US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who have also signed separate partnerships to develop new therapies for neurological diseases using RNA interference (RNAi) technology. ...

What is Genentech's partnership with Atalanta?

The strategic collaboration with Genentech entails the development of RNAi therapeutics for multiple CNS targets for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease. Atalanta will be eligible to receive development and milestone payments on these programs as well as royalty payments on any resulting products. ...

How will Atalanta benefit from Genentech?

Atalanta will be eligible to receive development and milestone payments on these programs as well as royalty payments on any resulting products. The strategic collaboration with Genentech entails the development of RNAi therapeutics for multiple CNS targets for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease. ...